Clinical application of vancomycin TDM in ventilated patients with gastrointestinal cancer: a propensity-matched analysis

Table 3 Comparison of pharmacokinetic parameters and patient demographics between C_trough and AUC

Characteristics	C_trough = 10-20 mg/L	AUC = 400–600	χ²	p value
Characteristics	(n = 23)	(n = 24)	χ²	p value
Age, years
Mean ± S.D	68.78 ± 10.45	71.75 ± 8.497		0.290^a
Median [range]	68 [61–76]	73 [64–78]
Sex, n(%)				1.000^c
Male	19 (82.6)	20 (83.3)
Female	4 (17.4)	4 (16.4)
Body weight, kg
Mean ± S.D	81.61 + 9.30	84.58 + 8.17		0.250^a
Median [range]	84 [75–88]	86 [77–91]
Apache II score on ICU
Mean ± S.D	19.65 + 3.60	18.75 + 2.85		0.345^a
Median [range]	20 [17–22]	18 [17–20]
SOFA score
Mean ± S.D	13.17 + 1.88	12.88 + 2.19		0.619^a
Median [range]	13 [12–14]	13 [11–14]
Albumin (g/L)
Mean ± S.D	28.10 + 6.53	27.58 + 4.81		0.754^b
Median [range]	29.40 [23.70–33.50]	28.30 [23.80–32.30]
Serum creatinine (μmol/L)
Mean ± S.D	79.00 + 26.24	70.92 + 32.14		0.351^b
Median [range]	76.00 [63.00–89.00]	59.50 [49.00–92.00]
Cys-C (mg/L)
Mean ± S.D	1.67 + 0.56	1.32 + 0.51		0.029*^a
Median [range]	1.60 [1.25–1.90]	1.21 [0.87–1.84]
Clinical Outcomes
Clinical success rate, n (%)	19 (82.6)	19 (79.2)	0.000	1.000^c
28-day all-cause mortality, n (%)	0	2 (8.3)		0.489^d
Composite outcome of new-onset AKI or RRT, n (%)	3 (13.0)	2 (8.3)	0.003	0.960^c

Abbreviations: C_trough trough concentration, APACHE II acute physiology and chronic health evaluation II, SOFA Sequential Organ Failure Assessment, Cys-C Cystatin C
Note: ^aStudent’s t test
^bMann–Whitney U test
^cPearson χ² test
^dFisher’s Exact Test
Values for categorical variables are given as count (percentage); values for continuous variables, as mean ± standard deviation or median [interquartile range]
^*p < 0.05

ISSN: 1471-2334